Nykode Therapeutics AS Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	6.77	8.68	12.9	7.17	33.96	215
Other Revenue	0.57	0.48	0.42	1.86	1.8	0.7
Revenue	7.35	9.16	13.32	9.03	35.77	215.7
Revenue Growth (YoY)	68.10%	-31.26%	47.56%	-74.76%	-83.42%	15175.85%
Gross Profit	7.35	9.16	13.32	9.03	35.77	215.7
Selling, General & Admin	18.47	31.55	28.42	18.8	17.51	16.41
Other Operating Expenses	13.28	23.69	40.87	41.57	28.3	20.72
Operating Expenses	33.83	57.49	71.41	62.19	46.54	37.43
Operating Income	-26.49	-48.33	-58.08	-53.16	-10.78	178.27
Interest Expense	-0.14	-0.19	-0.22	-0.24	-0.13	-0.05
Interest & Investment Income	4.28	7	8.95	3.69	0.27	0.2
Currency Exchange Gain (Loss)	5.71	-4	5.27	-1.24	-0.63	2.63
Other Non Operating Income (Expenses)	-0	-	-	-0.14	0.03	-0.21
EBT Excluding Unusual Items	-16.64	-45.51	-44.09	-51.09	-11.23	180.84
Gain (Loss) on Sale of Investments	-	-	-	0.1	0.12	0.07
Pretax Income	-16.64	-45.51	-44.09	-50.98	-11.12	180.9
Income Tax Expense	-5.64	-6.69	-8.93	-8.24	-1.7	31.13
Net Income	-11	-38.82	-35.15	-42.74	-9.41	149.77
Net Income to Common	-11	-38.82	-35.15	-42.74	-9.41	149.77
Shares Outstanding (Basic)	301	327	301	290	286	280
Shares Outstanding (Diluted)	301	327	301	290	286	296
Shares Change (YoY)	-22.32%	8.66%	3.58%	1.32%	-3.31%	1.14%
EPS (Basic)	-0.04	-0.12	-0.12	-0.15	-0.03	0.54
EPS (Diluted)	-0.04	-0.12	-0.12	-0.15	-0.03	0.51
Free Cash Flow	-35.77	-51.29	-98.53	-23.37	0.28	180.17
Free Cash Flow Per Share	-0.12	-0.16	-0.33	-0.08	0.00	0.61
Dividend Per Share	0.088	0.088	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-360.58%	-527.75%	-435.95%	-588.73%	-30.13%	82.65%
Profit Margin	-149.77%	-423.90%	-263.86%	-473.40%	-26.32%	69.44%
Free Cash Flow Margin	-486.99%	-560.07%	-739.52%	-258.81%	0.79%	83.53%
EBITDA	-25.75	-47.59	-57.45	-52.74	-10.69	178.3
EBITDA Margin	-	-	-	-	-29.89%	82.66%
D&A For EBITDA	0.74	0.74	0.63	0.42	0.09	0.03
EBIT	-26.49	-48.33	-58.08	-53.16	-10.78	178.27
EBIT Margin	-	-	-	-	-30.13%	82.65%
Effective Tax Rate	-	-	-	-	-	17.21%
Revenue as Reported	7.35	9.16	13.32	9.03	35.77	215.7

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.